Cantor Fitzgerald downgraded Longboard Pharmaceuticals to Neutral from Overweight after Lundbeck agreed to acquire Longboard for $60.00 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Morning Movers: Longboard Pharmaceuticals surges following deal to be acquired
- Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B
- Longboard Pharmaceuticals initiates DEEp SEA Study
- Longboard gets Rare Pediatric Disease, Orphan Drug designation for bexicaserin
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts